Headquartered in Carl Jacobsens Vej 30, Copenhagen Fiscal year ends December NASDAQ: GMAB genmab.com
Genmab is an international biotechnology company focused on developing innovative antibody-based medicines for cancer and other serious diseases. The company's technology platforms include bispecific antibodies (DuoBody), antibody-drug conjugates (ADCs), immune-modulating antibodies, and next-generation modalities such as HexaBody and DuoHexaBody. Genmab's business model combines proprietary product development with royalty streams from products licensed to major pharmaceutical partners. Its most significant commercial asset is DARZALEX (daratumumab), licensed exclusively to Johnson & Johnson for worldwide development, manufacturing, and commercialization, on which Genmab receives royalties. The company has eight approved antibody medicines and maintains a late-stage clinical pipeline including wholly owned programs. Genmab operates across North America, Europe, and Asia Pacific and trades on the Nasdaq under the ticker GMAB. Updated
With all eyes locked on this morning's CPI release and the Strait of Hormuz nearly shut down, Wall Street analysts are already repositioning across hospitality, pharma, and tech before the market even…
Pre-Market Stock Futures: Futures are trading lower as we prepare to end another up-and-down week, and, as we mentioned before, it all depends on the status of the war with Iran and…
Pre-Market Stock Futures: The futures are trading lower after a dreadful Friday and week, one that could be laying the foundation for a larger and more intense sell-off. The combination of the…
Genmab is an international biotechnology company focused on developing innovative antibody-based medicines for cancer and other serious diseases.
24/7 Wall St.'s 12-month price target for GMAB is $47.58, rated Buy. The Wall Street consensus target is $44.13. GMAB price prediction →
